Analysis for BMY

📈 Growth & Financial Trajectory

Over 8 quarters, Revenues rose from roughly $11.89B (Q3 2024) to $12.97B (Q2 2026), a positive but uneven trend due to quarterly swings. Net income expanded from about $1.21B to $3.32B, with notable peaks in Q1 2025 and Q1 2026 and mid-period dips in Q4 2024 and Q4 2025. Overall, the trajectory is favorable, though earnings volatility remains.

💰 Margins & Cash Flow

Gross margins stayed in the mid-70s percent, indicating strong product mix. Operating margins held around the 30% level across several quarters, supported by disciplined costs. Net cash flow from operating activities was positive in multiple quarters, underpinning liquidity despite fluctuations in investing/financing cash flows.

🛡️ Balance Sheet & Liquidity

Assets ($87.6B) exceed liabilities ($65.3B) with equity near $22.3B. Current ratio a healthy ~1.5, and cash generation supports serviceability of long-term debt.

⚠️ Key Drivers & Risks

• Drivers: diversified pharma portfolio; potential pipeline catalysts and label expansions.
• Risks: pipeline outcomes and regulatory/commercial pressures; high leverage and sensitivity to pharma cycles.